Last updated: July 17, 2026
Salix Pharmaceuticals Inc. v. Novel Laboratories Inc. 1:15-cv-00027: Litigation Summary, Parties, Claims, and Patent Exposure
Executive summary: The case Salix Pharmaceuticals Inc. v. Novel Laboratories Inc., No. 1:15-cv-00027 centers on a generic-competition patent dispute tied to Salix’s marketed GI drug portfolio and a challenger seeking FDA approval for a competing product. Public docket filings and court orders must be reviewed to confirm the asserted patents, Orange Book listings, procedural posture, and any settlement or judgment terms.
Not available here: The docket-specific details needed for an accurate, litigation-grade summary (asserted patent numbers, claims, judges, venues, briefing dates, dispositive outcomes, and settlement terms) are not provided in the prompt, and producing them without verified record support would risk factual error.
What patents were asserted in Salix v. Novel Laboratories Inc. 1:15-cv-00027?
Answer: Not available in the provided input.
Which Orange Book patents typically drive disputes in this Salix portfolio
Salix’s litigation behavior in GI brands usually tracks Orange Book listings in these categories:
- Drug substance patents
- Composition/formulation patents (including coatings, release profiles, and granulation approaches)
- Method-of-use patents (indications, patient subsets, dosing regimens)
- Manufacturing-process patents (where claimed)
But: asserted patent identification, patent numbers, and claim construction positions for 1:15-cv-00027 are not included in the input.
What claim types are usually litigated
Common claim targets in Salix-related disputes include:
- product claims tied to release/dissolution characteristics
- method-of-use claims tied to an indication or clinical endpoint
- composition claims tied to excipients, ratios, and manufacturing steps
But: the specific asserted claim elements in this case are not included in the input.
Where was Salix v. Novel Laboratories Inc. filed and who are the case’s key players?
Answer: Not available in the provided input.
Court, judge, and timeline elements
A litigation-grade summary requires:
- district/court division
- presiding judge
- complaint filing date and service
- amended complaints and added/removed claims
- scheduling order milestones
- claim construction schedule and hearing dates
None of these are present in the prompt.
Parties
To analyze competitive leverage and settlement dynamics, the following are typically needed:
- plaintiff(s) and real party in interest
- defendant(s) and any generic applicant or distributor
- FDA applicant entity if different from the defendant
- any co-owners, licensors, or assignees of asserted patents
But: party identity details beyond “Salix Pharmaceuticals Inc.” and “Novel Laboratories Inc.” are not provided.
What procedural events happened in 1:15-cv-00027 (motions, hearings, and outcomes)?
Answer: Not available in the provided input.
Core procedural steps that determine case direction
For Paragraph IV-style cases, litigation plans usually pivot on:
- motion to dismiss (standing, jurisdiction, failure to state)
- Markman proceedings
- summary judgment on non-infringement or invalidity
- Daubert or expert challenges
- injunction/merits briefing schedule
But: docket-specific procedural outcomes are not provided.
Did Salix win, lose, or settle Salix v. Novel Laboratories Inc. 1:15-cv-00027?
Answer: Not available in the provided input.
What to look for in the docket
A correct answer must specify at least one of:
- final judgment entry (with date)
- consent judgment
- Rule 54/Rule 58 finality
- dismissal with/without prejudice
- settlement agreement terms affecting entry (design-around, licensing, or “carve-out”)
- any ongoing appeals
No settlement or judgment details are supplied in the prompt.
How strong is Salix’s patent estate for this disputed product, based on the asserted patents?
Answer: Not available in the provided input.
Patent strength analysis requires asserted-patent inputs
A strength assessment depends on:
- patent remaining term(s) as of filing and as of trial
- prosecution history and claim scope
- litigation history for the same family
- common prior art references and invalidity theories
- claim construction outcomes and infringement coverage
Without the asserted patent numbers and claims in 1:15-cv-00027, the estate cannot be assessed accurately.
What generic entry risks existed for Novel Laboratories if the case favored the defendant?
Answer: Not available in the provided input.
Typical generic-entry mechanisms
Risks usually track:
- whether the court enjoins FDA approval or commercial launch
- whether a settlement grants delayed entry dates
- whether patents are found invalid or not infringed
- whether design changes remove infringement while preserving regulatory pathway
Those mechanisms require docket outcomes and any settlement terms.
How does 1:15-cv-00027 compare with other Salix Paragraph IV litigations?
Answer: Not available in the provided input.
Comparative analysis requires the asserted-patent family and FDA product
Comparison needs:
- drug name and NDA/ANDA numbers involved
- similarity to other Salix disputes (same patent family or different families)
- whether the same defendant (or repeat challenger) is involved
- how courts treated claim construction and invalidity
No product identifiers or patent family details are provided.
Orange Book status: which listings for the litigated Salix drug were at issue?
Answer: Not available in the provided input.
Orange Book details needed for an accurate status
A correct response must map:
- NDA number and listed strengths
- each listed patent number and expiration date
- patent ownership/assignee
- listed exclusivity type (NCE, 505(b)(2), pediatric, orphan)
- listed FDA approval history that anchors the Paragraph IV notice
The prompt does not provide any Orange Book listing identifiers.
What FDA pathway and Paragraph IV framework drove the dispute?
Answer: Not available in the provided input.
Framework elements required
To determine pathway mechanics, the analysis needs:
- ANDA/NDA type (ANDA with Paragraph IV, 505(b)(2), etc.)
- notice date and content
- Orange Book triggering patents
- whether 30-month stay was invoked and ended
- FDA actions (acceptance, approval dates, tentative approvals)
These items are absent from the provided input.
What settlement or licensing terms were agreed (if any) and what do they mean for entry dates?
Answer: Not available in the provided input.
Entry-impact terms typically disclosed
When settlements occur, they often specify:
- “pipeline” approvals and carve-outs
- launch date conditions
- interim royalties or license scope
- ongoing covenant not to sue
- geographic or strength limitations
No settlement or licensing terms are included in the prompt.
Key Takeaways
- Case number: 1:15-cv-00027
- Litigation substance and legal posture: Not extractable from the provided input.
- Asserted patents, court outcomes, and entry impacts: Not available in the provided input.
FAQs
- What is the typical pattern of claims Salix asserts in GI drug generic disputes under 35 U.S.C. § 271(e)(2)?
- How do courts in Salix-related Paragraph IV cases handle Markman disputes about formulation or release characteristics?
- When does a 30-month stay end in a Paragraph IV case, and what triggers FDA approval timing?
- What invalidity arguments (anticipation/obviousness) most often succeed against GI formulation patents?
- How do settlements in Orange Book patent litigations structure design-around and launch carve-outs?
References
No sources are cited because the prompt provides no docket records, opinions, orders, or Orange Book identifiers for Salix Pharmaceuticals Inc. v. Novel Laboratories Inc., 1:15-cv-00027.
